Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autogenous concentrated growth factor (CGF) is a third-generation platelet concentrate derived from the patient's own blood through a specialized centrifugation process using variable speeds. Unlike earlier generations such as Platelet-Rich Plasma (PRP) or Platelet-Rich Fibrin (PRF), CGF contains a denser fibrin matrix and a significantly higher concentration of growth factors and CD34+ stem cells. The preparation acts as a biological scaffold that slowly releases potent signaling molecules, including vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF-β1), and platelet-derived growth factor (PDGF). These components work synergistically to promote angiogenesis, stimulate fibroblast proliferation, and enhance collagen synthesis. In aesthetic medicine, CGF is primarily investigated for facial rejuvenation to treat signs of aging by repairing the extracellular matrix and improving skin elasticity and volume.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autogenous concentrated growth factor.